Follow us on Twitter
twitter icon@FreshPatents


Immune Response patents

      

This page is updated frequently with new Immune Response-related patent applications.




 Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity patent thumbnailnew patent Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity
The present application relates to anti-pd-l1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.. .
Genentech, Inc.


 Computationally optimized broadly reactive antigens for human and avian h5n1 influenza patent thumbnailnew patent Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
Described herein is the generation of optimized h5n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h5n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on human and avian h5n1 isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


 Cytokine-chitosan bioconjugates and methods of using the same patent thumbnailnew patent Cytokine-chitosan bioconjugates and methods of using the same
Compositions including chitosan covalently linked to a cytokine or growth factor are provided herein. The compositions can be used to produce pharmaceutical compositions and can be used in methods of treating a variety of diseases or disorders.
The Board Of Trustees Of The University Of Arkansas


 Cellular vaccine and  inducing an immune response in a subject patent thumbnailnew patent Cellular vaccine and inducing an immune response in a subject
The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein..
Adelaide Research & Innovation Pty Ltd.


 Influenza virus vectors and uses therefor patent thumbnailnew patent Influenza virus vectors and uses therefor
Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines.
Flugen, Inc.


 Haemophilus influenzae type iv pili patent thumbnailnew patent Haemophilus influenzae type iv pili
The invention described herein relates to a haemophilus influenzae (h. Influenzae) regulon encoding type iv pili.
Nationwide Children's Hospital, Inc.


 Influenza vaccine, composition, and methods of use patent thumbnailnew patent Influenza vaccine, composition, and methods of use
The invention relates to compositions and vaccines that include a mutated bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine..
National University Of Singapore


 Recombinant mycobacterium bovis bcg expressing antigens of the mycobacterium marinum esx-1 secretion system patent thumbnailnew patent Recombinant mycobacterium bovis bcg expressing antigens of the mycobacterium marinum esx-1 secretion system
Recombinant strains of mycobacterium bovis bacille calmette-guerin (m. Bovis bcg) comprising a heterologous nucleic acid sequence of mycobacterium marinum (m.
Institut Pasteur


 Multi-component-multistage malaria vaccines patent thumbnailnew patent Multi-component-multistage malaria vaccines
The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans.
Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.


 Methods and compositions for treating autoimmune and inflammatory conditions patent thumbnailnew patent Methods and compositions for treating autoimmune and inflammatory conditions
Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (apc)-targeted antibody operatively linked to il-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders..
Baylor Research Institute


new patent

Flavonoid compositions and methods of use

Flavonoid compositions containing the flavonoid quercetin and/or derivatives of quercetin are disclosed. The flavonoid compositions are formulated to improve the bioavailability of quercetin.
Reoxcyn Discoveries Group, Inc.

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Method for decreasing immunogenicity of protein and peptide

The present invention relates to a method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof by site-specifically binding a carrier to a protein or peptide, and to the use thereof. The conjugate of the physiologically active protein or peptide of the present invention can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide.
Hanmi Pharm. Co., Ltd.

Activation of immune-related signaling pathways in cells via optofection

Systems and methods of inducing large-scale optical transfection and generation of an immune response in target cells are presented. In preferred aspects large-scale optofection uses nanoparticles with target specific affinity moieties to generate cavitation events proximal to the cell membrane of cells to which the nanoparticles are attached, and suspended and/or dissolved cargo is so provided access into the cell.
Nant Holdings Ip, Llc

Induction of mucosal tolerance to antigens

The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of foxp3+ and/or il-10 and/or tgf-β producing regulatory t-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism..
Intrexon Actobiotics Nv

Combination vaccines with serogroup b meningococcus and d/t/p

Serogroup b meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“dtp”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type dtp ratios.
Glaxosmithkline Biologicals Sa

Amplification of epitope specific personalized anti-angiogenic immune responses

Disclosed are therapeutic means, protocols, and compositions of matter useful for treatment of cancer by eliciting and amplifying immune responses specific to antigens found on tumor endothelium. In one embodiment of the invention a patient is immunized with a polyvalent anti-angiogenic vaccine, subsequent to which assessment is made in a patient specific manner of the immune targets that are recognized in response to the immunizing mixture.
Batu Biologics, Inc.

Strategies to prevent and/or treat immune responses to soluble allofactors

The present invention relates to the use of immunogenic peptides comprising a t-cell epitope derived from a soluble allofactor and a redox motif such as c-(x)2-[cst] or [cst]-(x)2-c in the prevention and/or suppression of immune responses to said soluble allofactor and in the manufacture of medicaments therefore.. .
Life Sciences Research Partners Vzw

Methods and compositions for immunomodulation

The methods and uses described herein relate to the modulation of the immune system by modulation of sema3f levels and/or activity, e.g. Suppressing allograft rejection or inflammation by administering a sema3f agonist or increasing an immune response by administering a sema3f inhibitor..
Children's Medical Center Corporation

Treatment of glioma by anti-angiogenic active immunization for direct tumor inhibition and augmentation of chemotherapy, immunotherapy and radiotherapy efficacy

Disclosed are compositions of matter, therapeutic protocols, and immunization means to induce an active immune response to vasculature feeding glioma or other brain neoplasia. In one embodiment the invention provides administration of placental derived endothelial cells at concentrations of 10 million to 50 million administered in a manner to stimulate immunity toward blood vessels supplying glioma or other brain neoplastic malignancies.
Batu Biologics, Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses

The invention relates to a chimeric protein comprising or consisting of, from n-terminal to c-terminal, (a) a n-terminal part of a bordetella cyaa protein (b) a heterologous polypeptide, and (c) a c-terminal part of a bordetella cyaa protein. The invention also relates to a polynucleotide encoding a deleted version of a bordetella cyaa, as well as a polynucleotide encoding this chimeric protein.
Genticel

Inhibition of gliadin peptides

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Amino acid and peptide conjugates and conjugation process

The present invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions comprising the conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same.. .
Auckland Uniservices Limited

Inhibition of tumor angiogenesis by checkpoint inhibitors and active vaccination

Disclosed are compositions of matter, methods, and protocols useful for treatment of cancer through induction of anti-angiogenic immune responses by vaccination together with immune modulation triggered by checkpoint inhibitors. The invention provides placenta, placental endothelial, placental fibroblasts, and mixtures thereof as immunogens, whose anti-angiogenic activity is augmented by utilization of checkpoint inhibitors.
Batu Biologics, Inc.

Lectin compositions and methods for modulating an immune response to an antigen

The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide.
Opsanitx Llc

Methods and compositions for eliciting an immune response against hepatitis b virus

The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis b virus in individuals in need thereof..
Dynavax Technologies Corporation

Hendra virus recombinant compositions and uses thereof

The present invention provides vectors that contain and express in vivo or in vitro one or more hendra virus polypeptides or antigens that elicit an immune response in animal or human against hendra virus and nipah virus, compositions comprising said vectors and/or hendra virus polypeptides, methods of vaccination against hendra virus and nipah virus, and kits for use with such methods and compositions.. .
Merial, Inc.

Medicament for use in a inducing or extending a cellular cytotoxic immune response

The present invention relates to a medicament for use in a method of extending a cellular cytotoxic immune response against an antigen-comprising protein, the method comprising the step of: i) administering to a patient having t cells activated against an antigen a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and an adjuvant which supports a th-1-mediated response, wherein the peptide is derived from the antigen-comprising protein, thereby re-activating the activated t cell, wherein the peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell of step i) is administered in a time frame of from 0 h to 14 days after the t cells were activated against an antigen.. .
Bundesrepublik Deutschland Ietzvertreten Durch Das Robert Koch-institut Vertreten Durch Seinen Präsi

Genetic engineering of macrophages for immunotherapy

Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (tme) and methods of modifying a tumor microenvironment (tme). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces t-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred nk or t cells and/or induces production of an interleukin, an interferon, a pd-1 checkpoint binding protein, hmgb1, myd88, a cytokine or a chemokine.
Seattle Children's Hospital (dba Seattle Children' S Research Institute)

Recombinant poxvirus vector comprising tetanus toxin fragment c

The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment c for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment c (ttc) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject..
Bavarian Nordic A/s

Immunomodulating beta-1,6-d-glucans

This invention relates to modifications of β-1,6-d-glucans, e.g., structures according to formula (i), and the ability of these compositions to modulate an immune response.. .
Immunexcite, Inc.

Regulatable chimeric antigen receptor

Provided are compositions and methods relating to regulatable chimeric antigen receptors (rcars), natural killer cell receptor cars (nkr-cars), and regulatable nkr-cars (rnkr-cars), where the intracellular signaling or proliferation of the rcar or rnkr-car can be controlled to optimize the use of an rcar/nkr-car- or rnkr-car-expressing cell to provide an immune response. Cells can be engineered to express a rnkr-car or to express a rcar and a nkr-car (e.g., inhibitory nkr-car).
The Trustees Of The University Of Pennsylvania

Mesothelin-targeted chimeric antigen receptors and uses thereof

The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (cars) that specifically target human mesothelin, and immunoresponsive cells comprising such cars.
The U.s.a. As Represented By The Secretary, Department Of Health And Human Services

Peptide antagonist of ll-37

This disclosure is related to the peptide antagonist of ll-37, an antimicrobial peptide that has multiple functions in both innate and adaptive immune response. Specifically, the identified peptide antagonists of ll-37 provide inhibition to detrimental autoimmune inflammatory response, whereas at the same time retain ll-37's antibacterial activity..
Janssen Biotech, Inc.

Composition and diagnosis and immunotherapy of lung cancer

The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic t lymphocyte specific immune response to at least one of sp17, akap-4, or pttg1 expressed by one or more lung cancer cells.. .
Texas Tech University System

Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Modified adenoviruses for cancer vaccines development

The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g.
Helsingin Yliopisto

A medicament for use in a inducing or extending a cellular cytotoxic immune response

The present invention relates to a medicament for use in a method of inducing a cellular cytotoxic immune response, the method comprising the steps of: i) administering to a patient a delivery system comprising (a) a molecule binding to a receptor on the surface of a dendritic cell, (b) an antigen-comprising protein bound to molecule of (a) and (c) a first adjuvant, wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the dendritic cell and the antigen comprised in the protein is presented on the surface of the dendritic cell, thereby activating a t cell in the patient; and ii) administering to the patient a re-activator selected from the group consisting of (d) complexed interleukin 2 (il-2cx), (e) a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and a second adjuvant, and (f) a combination of (d) and (e), wherein the peptide is derived from the antigen-comprising protein as defined in step i), thereby reactivating the t cell activated in step i), wherein the re-activator of step ii) is administered in a time frame of from 0 h to 14 days after the administration of the delivery system of step i).. .
Bundesrepublik Deutschland Ietztvertreten Durch Da S Robert Koch-institut Vertreten Durch Seinen Prä

Methods and compositions for increasing a t-effector cell to regulatory t cell ratio

The present invention is directed to methods for increasing t-cell effector cell to regulatory t cell ratio. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering to a subject a recombinant listeria strain, comprising a fusion peptide that comprises an llo fragment and tumor-associated antigen..
National Institutes Of Health (nih), U.s. Dept. Of Health And Humans Services (dhhs), U.s. Governmen

Flavonoid compositions and methods of use

Flavonoid compositions containing the flavonoid quercetin and/or derivatives of quercetin are disclosed. The flavonoid compositions are formulated to improve the bioavailability of quercetin.
Reoxcyn Discoveries Group, Inc.

Humanized monoclonal antibodies and methodsof use

The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene vh1-69. This antibody is derived from mab g6 and recognizes the same epitope.
Dana-farber Cancer Institute, Inc.

Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function

Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
St. Jude Children's Research Hospital

Compositions and methods for anti-lyst immunomodulation

Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the lyst protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage.
Research Institute At Nationwide Children's Hospital

Particulate vaccine formulations for inducing innate and adaptive immunity

Disclosed are compositions, kits, and methods for inducing an immune response against an infection or a disease. The compositions typically include biodegradable particles having an average effective diameter that such that the biodegradable particles are phagocytosed by antigen presenting cells when the biodegradable particles are administered to a subject in need thereof.
Auburn University

A composition comprising ex-vivo generated dendritic cells

The present invention relates to a composition comprising ex-vivo generated antigen-loaded dendritic cells in combination with β-glucan and hyaluronic acid or pharmaceutically acceptable derivatives thereof and methods of preparing and delivering the same. The present composition of the present invention enhances antigen-specific t cell response against cancer cells.

Novel immunogenic composition

Recombinant chimeric viruses based on ndv lasota strain and containing either iltv gb or gd are produced. Administration of the chimeric viruses to chickens induces an immune response in the animal against both ndv and iltv.
The United States Of America, As Represented By The Secretary Of Agriculture

Multivalent vlp conjugates

The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (vlp), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents.
Inventprise, Llc

Antigen specific multi epitope vaccines

The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple mhc class i and class ii epitopes which are highly abundant in the population.
Vaxil Biotherapeutics Ltd.

Tumor vaccination involving a humoral immune response against self-proteins

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis b virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject..
Biontech Ag

Prenatal therapy to induce immune tolerance

Constructs and methods for inducing immune tolerance during gestation, e.g. In utero, are provided.
Inserm (institut National De La Santé Et De La Recherche Médicale)



Immune Response topics:
  • Immune Response
  • Antibodies
  • Polypeptide
  • Monoclonal
  • Monoclonal Antibody
  • Polymyxin B
  • Immunostimulator
  • Vaccination
  • Stimulator
  • Immunogenic
  • Nucleic Acid
  • Major Histocompatibility Complex
  • Histocompatibility
  • Vaccine Adjuvant
  • Compatibility


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immune Response for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Response with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.7185

    file did exist - 2755

    2 - 1 - 54